U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C15H23NO2S.ClH
Molecular Weight 317.875
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OSU-6162 HYDROCHLORIDE

SMILES

Cl.CCCN1CCC[C@H](C1)C2=CC(=CC=C2)S(C)(=O)=O

InChI

InChIKey=LEMGVHZVBREXAD-PFEQFJNWSA-N
InChI=1S/C15H23NO2S.ClH/c1-3-9-16-10-5-7-14(12-16)13-6-4-8-15(11-13)19(2,17)18;/h4,6,8,11,14H,3,5,7,9-10,12H2,1-2H3;1H/t14-;/m1./s1

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C15H23NO2S
Molecular Weight 281.414
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

PNU-96391A (known as OSU6162) is a weak dopamine (DA) D(2) receptor antagonist with behavioral stabilizing properties. OSU6162 seem to act as stabilizers not only on dopaminergic, but also on serotonergic brain signaling (partial agonist on 5-HT2A receptor). OSU6162 in a phase II European clinical trial in treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. One of the isomer of OSU 6162, has promise for treating Parkinson's disease, Huntington's disease and schizophrenia, but both enantiomers of OSU 6162 had dual effects on behavior, stimulating locomotor activity in 'low activity' animals and inhibiting locomotor activity in 'high activity' animals.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Modulator
828
 447.0 nM [Ki]
Modulator
828
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.245 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.0178 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.543 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.1 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.19 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.2 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.372 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.038 μM
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2.27 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.24 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.18 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
12.53 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
14.8 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
6.87 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
1.69 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
0.223 μM × h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.89 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
7.94 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.32 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5.37 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
N-DEPROPYL-(-)-OSU 6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.66 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.39 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.33 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
30 mg single, oral
dose: 30 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
3.77 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/14973308/
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
OSU-6162 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
45 mg 2 times / day multiple, oral (unknown)
Highest studied dose
Dose: 45 mg, 2 times / day
Route: oral
Route: multiple
Dose: 45 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30132786
unhealthy
n = 28
Health Status: unhealthy
Condition: multiple sclerosis
Sex: M+F
Food Status: UNKNOWN
Population Size: 28
Sources:
https://pubmed.ncbi.nlm.nih.gov/30132786
Other AEs: Fatigue, Headache...
Other AEs:
Fatigue (3.6%)
Headache (7.1%)
Nasopharyngitis (3.6%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/30132786
AEs

AEs

AESignificanceDosePopulation
Fatigue 3.6%
45 mg 2 times / day multiple, oral (unknown)
Highest studied dose
Dose: 45 mg, 2 times / day
Route: oral
Route: multiple
Dose: 45 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30132786
unhealthy
n = 28
Health Status: unhealthy
Condition: multiple sclerosis
Sex: M+F
Food Status: UNKNOWN
Population Size: 28
Sources:
https://pubmed.ncbi.nlm.nih.gov/30132786
Nasopharyngitis 3.6%
45 mg 2 times / day multiple, oral (unknown)
Highest studied dose
Dose: 45 mg, 2 times / day
Route: oral
Route: multiple
Dose: 45 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30132786
unhealthy
n = 28
Health Status: unhealthy
Condition: multiple sclerosis
Sex: M+F
Food Status: UNKNOWN
Population Size: 28
Sources:
https://pubmed.ncbi.nlm.nih.gov/30132786
Headache 7.1%
45 mg 2 times / day multiple, oral (unknown)
Highest studied dose
Dose: 45 mg, 2 times / day
Route: oral
Route: multiple
Dose: 45 mg, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/30132786
unhealthy
n = 28
Health Status: unhealthy
Condition: multiple sclerosis
Sex: M+F
Food Status: UNKNOWN
Population Size: 28
Sources:
https://pubmed.ncbi.nlm.nih.gov/30132786
Sourcing

Sourcing

Vendor/AggregatorIDURL
Alfa Chemistry
9297
http://www.alfa-chemistry.com/search.aspx?q=9297
Alfa Chemistry
AFI156907845
http://www.alfa-chemistry.com/search.aspx?q=AFI156907845
Angene
AGN-PC-0O3DIT
http://www.angenechemical.com/productshow/AGN-PC-0O3DIT.html
BOC Sciences
146798-66-5
http://www.bocsci.com/description.asp?cas=146798-66-5
BOC Sciences
156907-84-5
http://www.bocsci.com/description.asp?cas=156907-84-5
BioSynth
J-501275
https://www.biosynth.com/en/products/life-science/other-biochemicals/products/J-501275
MolPort
MolPort-023-276-502
https://www.molport.com/shop/molecule-link/MolPort-023-276-502
MuseChem
I010589
https://www.musechem.com/product/I010589.html
MuseChem
R006458
https://www.musechem.com/product/R006458.html
MuseChem
R012240
https://www.musechem.com/product/R012240.html
Tocris
2599
https://www.tocris.com/search.php?Type=QuickSearch&Value=2599
Toronto Research Chemicals
O006162
https://www.trc-canada.com/product-detail/?CatNum=O006162
Wonderchem
WD0582Z
http://www.wonder-chem.com/search.html?text=WD0582Z
Wonderchem
WD05AG4
http://www.wonder-chem.com/search.html?text=WD05AG4
eMolecules
31591103
https://orderbb.emolecules.com/search/#?query=31591103
eMolecules
36500597
https://orderbb.emolecules.com/search/#?query=36500597
eMolecules
48542828
https://orderbb.emolecules.com/search/#?query=48542828
mcule
MCULE-1147545508
https://mcule.com/MCULE-1147545508/
mcule
MCULE-5862763060
https://mcule.com/MCULE-5862763060/
PubMed

PubMed

TitleDatePubMed
Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions.
2001 May
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonylphenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat.
2006 Aug
II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.
2011 Nov
The Effects of (-)-OSU6162 on Chronic Fatigue in Patients With Traumatic Brain Injury: A Randomized Controlled Trial.
2017 Mar/Apr
Patents

Patents

US2010197760
2
US2013197032
2
US6841557
2
US8188301
2
US8793078
2

Sample Use Guides

In Vivo Use Guide
OSU6162 of 30-60 mg/day
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: To elucidate a plausible mechanism of action for both enantiomers of OSU6162, it was evaluated the intrinsic actions of (-)- and (+)-OSU6162, and a collection of other antipsychotic and antiparkinsonian agents at 5-HT2A and D2 receptors in functional assays with various degrees of receptor reserve, including cellular proliferation, phosphatidyl inositol hydrolysis, GTPγS and beta-arrestin recruitment assays. Both enantiomers of OSU6162 were medium intrinsic activity partial agonists at 5-HT2A receptors and low intrinsic activity partial agonists at D2 receptors.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:30:51 GMT 2023
Edited
by admin
on Fri Dec 15 15:30:51 GMT 2023
Record UNII
V5SBJBUJW6
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OSU-6162 HYDROCHLORIDE
Code English
PIPERIDINE, 3-(3-(METHYLSULFONYL)PHENYL)-1-PROPYL-, HYDROCHLORIDE, (S)-
Systematic Name English
3-(3-METHANESULFONYL-PHENYL)-1-PROPYL-PIPERIDINE HYDROCHLORIDE
Common Name English
Classification Tree Code System Code
EU-Orphan Drug 3-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine hydrochloride
Created by admin on Fri Dec 15 15:30:51 GMT 2023 , Edited by admin on Fri Dec 15 15:30:51 GMT 2023
Code System Code Type Description
FDA UNII
V5SBJBUJW6
Created by admin on Fri Dec 15 15:30:51 GMT 2023 , Edited by admin on Fri Dec 15 15:30:51 GMT 2023
PRIMARY
EPA CompTox
DTXSID40431531
Created by admin on Fri Dec 15 15:30:51 GMT 2023 , Edited by admin on Fri Dec 15 15:30:51 GMT 2023
PRIMARY
CAS
156907-84-5
Created by admin on Fri Dec 15 15:30:51 GMT 2023 , Edited by admin on Fri Dec 15 15:30:51 GMT 2023
PRIMARY
EVMPD
SUB193816
Created by admin on Fri Dec 15 15:30:51 GMT 2023 , Edited by admin on Fri Dec 15 15:30:51 GMT 2023
PRIMARY
PUBCHEM
9836644
Created by admin on Fri Dec 15 15:30:51 GMT 2023 , Edited by admin on Fri Dec 15 15:30:51 GMT 2023
PRIMARY
SMS_ID
100000178208
Created by admin on Fri Dec 15 15:30:51 GMT 2023 , Edited by admin on Fri Dec 15 15:30:51 GMT 2023
PRIMARY
Related Record Type Details
Structure of OSU-6162
PARENT -> SALT/SOLVATE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966